MLMarc Van Leersum

Marc Van Leersum

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marc Van Leersum has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 15 January 2016
      • Vol. 57  (2) , 158-61

    Is a history of radiation therapy a contraindication for carotid surgery?

    by Jan A Vos, Marc Van Leersum, Jean P De Vries

    Advances in surgical and medical oncology have seen a significant increase in survival of patients suffering from head and neck malignancies. Many of these patients are treated with radiotherapy to the neck, including the cervical carotid artery. Cervical irradiation (CI) may induce carotid stenosis. Prior CI in association with carotid artery stenosis poses potential challenges, when revascularization is considered. As the focus of radiotherapy determines the level of the resultant obstruction it may be in a location that is difficult to reach surgically. Also scar tissue from CI may increase the risk of cranial nerve injury. Carotid angioplasty and stenting (CAS) may be an alternative for CEA in post CI cases. This manuscript aims to derive a treatment algorithm for post CI stenosis from the available literature, answering three questions: 1) do symptomatic post CI stenoses require revascularization?; 2) Do asymptomatic post CI stenoses require revascularization?; 3) What is the preferred revascularization modality? The answers to those questions are the following: 1) as several studies have shown the increased likelihood of stenosis after CI and its potential for embolic events, symptomatic stenosis should be treated; 2) patients after CI have a much greater chance of serious events from their malignancies than from their carotid disease, therefore most asymptomatic stenoses probably do not warrant revascularization; 3) CEA post CI carries less peri procedural risk than previously supposed and CAS is hampered by increased restenosis rates, so CEA should be the preferred treatment if feasible. An individual patient tailored approach for post CI carotid stenosis is warranted, the guideline being: "If symptomatic: revascularize; if possible: operate; if not: consider stenting".


  • Initial Results of Catheter-Directed Ultrasound-Accelerated Thrombolysis for Thromboembolic Obstructions of the Aortofemoral Arteries: A Feasibility Study

    by A. Marjolein Schrijver, Michel M. P. J. Reijnen, Jacques A. van Oostayen, Arjan W. J. Hoksbergen, Rutger J. Lely, Marc van Leersum, Jean-Paul P. M. de Vries

    Purpose This article reports the 30-day technical and clinical outcome of ultrasound (US)-accelerated thrombolysis in patients with aortofemoral arterial thromboembolic obstructions. Methods A prospective cohort study was conducted from December 2008 to December 2009 of patients who were treated with US-accelerated thrombolysis for thromboembolic obstructions of aortofemoral arteries or bypasses. Urokinase was infused in a dosage of 100,000 IU per hour. Twice daily, a control angiography was performed. Thirty-day follow-up consisted of duplex scanning, combined with magnetic resonance angiography. Results The study included 21 consecutive patients (20 men; median age, 66 (range, 52–80) years) with 24% artery versus 76% bypass occlusions. Median duration of symptoms was 11 (range, 7–140) days. Median occlusion length was 32 (range, 6–80) cm. In 20 patients (95%), an US-accelerated thrombolysis catheter could be successfully placed. In one patient, placement of an US-accelerated thrombolysis catheter was technically not feasible, and therefore a standard catheter was placed. Median thrombolysis time was 26.5 (range, 8.5–72) hours. Complete thrombolysis (>95% lysis of thrombus) was achieved in 20 patients; in 9 patients within 24 hours. Median ankle-brachial index (ABI) increased from 0.28 (range, 0–0.85) to 0.91 (range, 0.58–1.35). One patient had a thromboembolic complication and needed surgical intervention. No hemorrhagic complications, and no deaths occurred. At 30-day follow-up, 17 of 21 patients (81%) had a patent artery or bypass. Conclusions This feasibility study showed a high technical success rate of US-accelerated thrombolysis for aortofemoral arterial obstructions. US-accelerated thrombolysis led to complete lysis within 24 hours in almost half of patients, with a low 30-day major complication rate.


  • Open Access

    Dutch randomized trial comparing standard catheter-directed thrombolysis versus Ultrasound-accElerated Thrombolysis for thromboembolic infrainguinal disease (DUET): design and rationale

    by A Marjolein Schrijver, Michel Mpj Reijnen, Jacques A van Oostayen, Rudolf Pj Tutein Nolthenius, Pieter Hm van der Valk, Arjan Wj Hoksbergen, Rutger J Lely, Bram Fioole, Dammis Vroegindeweij, Marc van Leersum, et al.

    Background: The use of thrombolytic therapy in the treatment of thrombosed infrainguinal native arteries and bypass grafts has increased over the years. Main limitation of this treatment modality, however, is the occurrence of bleeding complications. Low intensity ultrasound (US) has been shown to accelerate enzymatic thrombolysis, thereby reducing therapy time. So far, no randomized trials have investigated the application of US-accelerated thrombolysis in the treatment of thrombosed infra-inguinal native arteries or bypass grafts. The DUET study (Dutch randomized trial comparing standard catheter-directed thrombolysis versus Ultrasound-accElerated Thrombolysis for thrombo-embolic infrainguinal disease) is designed to assess whether US-accelerated thrombolysis will reduce therapy time significantly compared with standard catheter-directed thrombolysis. Methods/design: Sixty adult patients with recently (between 1 and 7 weeks) thrombosed infrainguinal native arteries or bypass grafts with acute limb ischemia class I or IIa, according to the Rutherford classification for acute ischemia, will be randomly allocated to either standard thrombolysis (group A) or US-accelerated thrombolysis (group B). Patients will be recruited from 5 teaching hospitals in the Netherlands during a 2-year period. The primary endpoint is the duration of catheter-directed thrombolysis needed for uninterrupted flow in the thrombosed infrainguinal native artery or bypass graft, with outflow through at least 1 crural artery. Discussion: The DUET study is a randomized controlled trial that will provide evidence of whether US-accelerated thrombolysis will significantly reduce therapy time in patients with recently thrombosed infrainguinal native arteries or bypass grafts, without an increase in complications. Trial registration: Current Controlled Trials ISRCTN72676102


    • 7 February 2009
      • Vol. 153  (6) , 228-31

    [Critical ischemia in the leg by two different kinds of deep venous thrombosis. Phlegmasia alba dolens en phlegmasia caerulea dolens].

    by Lars Van Bindsbergen, Bram Fioole, Rutger J Hissink, Marc Van Leersum, Frans L Moll, Jean-Paul P M De Vries